ADC Therapeutics SA

The firm's antibody-drug conjugates use pyrrolobenzodiazepine dimers — chemical warheads that bind to and cross-link tumor cell DNA, triggering cell death. Unlike earlier-generation chemotherapy linkers, PBD dimers can kill tumor cells that are not actively dividing. The antibody component targets specific surface receptors like CD19 on lymphoma cells, which the company claims reduces off-target toxicity compared to conventional chemo regimens.

No. Like most single-product biotechs, the firm has not reached sustained profitability. Zynlonta net product revenue for the first full year of launch came in at roughly $33.8 million in 2021, well below the cash burn from R&D and commercial infrastructure. The Sobi licensing deal from May 2023 and royalty-backed debt from Blue Owl have provided non-dilutive runway, but operating losses remain the near-term expectation.

No single family controls the firm. ADC Therapeutics is a widely held NYSE-listed company. Auven Therapeutics, the original private equity incubator, distributed shares to Auven's limited partners at the 2020 IPO. Institutional holders as of public filings include Redmile Group, Aviva Investors, and BNP Paribas affiliates, none with disclosed controlling stakes.

Zynlonta received accelerated FDA approval in April 2021 based on single-arm Phase 2 data. The confirmatory Phase 3 LOTIS-5 trial, comparing Zynlonta plus rituximab against standard chemo-immunotherapy in second-line diffuse large B-cell lymphoma, is the required post-marketing study. Results will determine whether the accelerated approval converts to full regulatory approval; the firm has guided for data in 2025.

Only selectively, and not as a standalone licensing business. The Spirogen platform was originally a licensable warhead chemistry used by other biotechs, but since AstraZeneca's acquisition of Spirogen in 2013, third-party access narrowed. ADC Therapeutics' current pipeline is wholly owned, with partnerships structured as specific product rights transactions — like the Sobi Zynlonta deal — rather than broad platform licenses.

Significant and concentrated. Beyond the LOTIS-5 confirmatory readout, the firm has multiple trials in hematologic and solid tumor indications. A clinical setback in LOTIS-5 — which is a company-defining binary event — would materially reduce Zynlonta's addressable US market and likely force a restructuring. The firm's single-modality focus means risk is undiversified across programs or drug classes.

Seagen operates at roughly 10x the commercial scale with four approved drugs and a marketing partnership with Takeda, plus a $43 billion acquisition by Pfizer announced in 2023. ADC Therapeutics is a single-product company with no pharma anchor partner for its US commercial business. The comparison is meaningfully one of scale, pipeline breadth, and balance-sheet strength — ADC is a mono-product ADC story where Seagen was the diversified platform.